- Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease2009 | First Faculty of Medicine
- The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease2007 | Third Faculty of Medicine
- Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study2023 | First Faculty of Medicine
- Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis2020 | First Faculty of Medicine
- Fabry disease: overall effects of agalsidase alfa treatment2004 | First Faculty of Medicine
- Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial2019 | First Faculty of Medicine
- Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study2020 | Publication without faculty affiliation
- Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data2009 | First Faculty of Medicine
- Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease2022 | First Faculty of Medicine
- Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: Data from the Fabry Registry2016 | First Faculty of Medicine
- Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered - Authors' reply2015 | First Faculty of Medicine
- Effect of Agalsidase Alfa Replacement Therapy on Fabry Disease-Related Hypertrophic Cardiomyopathy: A 12-to 36-Month, Retrospective, Blinded Echocardiographic Pooled Analysis2009 | First Faculty of Medicine
- FOS - Fabry outcome survey - is a useful tool to document Fabry disease and effects of agalsidase alfaPublication without faculty affiliation
- Improved renal function under agalsidase alfa treatment in Fabry patientsPublication without faculty affiliation
- Improved renal function under agalsidase alfa treatment in Fabry patients (1)Publication without faculty affiliation
- Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis2021 | First Faculty of Medicine
- Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study2023 | First Faculty of Medicine
- FOS - the Fabry Outcome Survey - is a useful tool to document Fabry disease and effects of agalsidase alfaPublication without faculty affiliation
- Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch2014 | Central Library of Charles University
- Positive European experience with agalsidase alfa in Fabry disease: update from FOS - the Fabry Outcome Survey +1Publication without faculty affiliation
- Fabry disease: beneficial long-term effects of agalsidase alfe confirmed in FOS - the Fabry Outcome SurveyPublication without faculty affiliation
- Safety of agalsidase alfa enzyme replacement therapy in a cohort of 1329 patients in FOS - The Fabry Outcome SurveyPublication without faculty affiliation
- Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease2015 | First Faculty of Medicine
- Léčba Fabryho choroby - agalsidáza alfa versus agalsidáza beta, mezinárodní studie : komentář2018 | First Faculty of Medicine
- The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts2019 | First Faculty of Medicine
- Long-term follow-up in FOS - the Fabry Outcome Survey - confrims beneficial effects of agalsidase alfa on renal and other manifestations of Fabry diseasePublication without faculty affiliation
- Prevalence of neuropathic pain and stroke in patients with Fabry disease enrolled in FOS - Fabry Outcome Survey - before and after enzyme replacement therapy with agalsidase alfaPublication without faculty affiliation
- Effect of enzyme replacement therapy with agalsidase alfa on left ventricular mass in patients with Anderson Fabry disease: two-year results from FOS- the Fabry Outcome SurveyPublication without faculty affiliation
- Effect of enzyme replacement therapy with agalsidase alfa on left ventricular mass in patients with Anderson Fabry disease: two-year results from FOS - the Fabry Outcome SurveyPublication without faculty affiliation